| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 7,981 | $114.00 | $909,841.18 | - | |
| Nov 11, 2019 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Vice President, Finance | Sell | 5,000 | $43.59 | $217,950.00 | -32.0% | |
| Nov 11, 2019 | TLPH Talphera, Inc. | Angotti Vincent J.56 | Chief Executive Officer | Buy | 8,379 | $1.79 | $14,973.27 | +3.1% | |
| Nov 11, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 100 | $114.07 | $11,406.50 | - | |
| Nov 11, 2019 | PRGO Perrigo Co Plc | Quinn Grainne | EVP, Chief Medical Officer | Sell | 2,050 | $49.08 | $100,614.00 | -40.2% | |
| Nov 11, 2019 | AMRN Amarin Corp Plc\uk | Thero John F | President And CEO | Sell | 475,546 | $17.12 | $8,143,451.79 | -8.3% | |
| Nov 11, 2019 | HROW Harrow, Inc. | Kammer Robert J | Director | Sell | 6,500 | $4.75 | $30,875.00 | -0.8% | |
| Nov 8, 2019 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 3,082 | $54.15 | $166,884.44 | -14.3% | |
| Nov 8, 2019 | IRWD Ironwood Pharmaceuticals Inc | Consylman Gina | SVP, CFO &Treasurer | Sell | 1,510 | $11.00 | $16,610.00 | -0.4% | |
| Nov 8, 2019 | CVSI Cv Sciences, Inc. | Dowling Joseph D | CEO | Buy | 15,000 | $1.65 | $24,750.00 | New | |
| Nov 8, 2019 | COLL Collegium Pharmaceutical, Inc | Hirsch David | Director | Sell | 25,000 | $19.33 | $483,250.00 | -59.4% | |
| Nov 8, 2019 | PCRX Pacira Biosciences, Inc. | Scranton Richard | Chief Scientific Officer | Sell | 19,448 | $45.00 | $875,160.00 | -54.8% | |
| Nov 8, 2019 | IRWD Ironwood Pharmaceuticals Inc | MacDonald Kelly | Chief Accounting Officer | Sell | 987 | $11.00 | $10,857.00 | -0.6% | |
| Nov 8, 2019 | PRGO Perrigo Co Plc | Janish Ronald Craig61 | EVP, Global Op. &Supply Chain | Sell | 2,424 | $49.90 | $120,967.30 | -28.8% | |
| Nov 8, 2019 | COLL Collegium Pharmaceutical, Inc | Fleming Alison B | Chief Technology Officer | Sell | 25,000 | $19.44 | $486,000.00 | -25.4% | |
| Nov 8, 2019 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 10,000 | $110.01 | $1,100,057.38 | -19.9% | |
| Nov 8, 2019 | NBIX Neurocrine Biosciences Inc | Lyons Gary A54 | Director | Sell | 5,000 | $110.00 | $550,000.00 | -2.2% | |
| Nov 8, 2019 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 100,000 | $19.78 | $1,978,444.86 | -6.5% | |
| Nov 8, 2019 | ANIK Anika Therapeutics, Inc. | Cheung Sylvia | Chief Financial Officer | Sell | 20,000 | $59.71 | $1,194,200.00 | -29.5% | |
| Nov 7, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 400 | $114.37 | $45,749.00 | - | |
| Nov 7, 2019 | COLL Collegium Pharmaceutical, Inc | Ciaffoni Joseph | President And CEO | Sell | 64,821 | $18.77 | $1,216,774.11 | -14.4% | |
| Nov 7, 2019 | EBS Emergent Biosolutions Inc. | Richard Ronald | Director | Sell | 5,153 | $60.00 | $309,180.00 | -16.2% | |
| Nov 7, 2019 | CVSI Cv Sciences, Inc. | Grasser Joerg | CFO | Buy | 15,000 | $1.49 | $22,288.50 | New | |
| Nov 7, 2019 | BUDZ Weed, Inc. | Breen Nicole M | Secretary And Treasurer | Sell | 66,000 | $0.40 | $26,280.00 | - | |
| Nov 6, 2019 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 173,918 | $114.05 | $19,835,000.06 | -0.1% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.